The company, which is developing cancer therapies by using DNA sequencing from individual patients, signed a three-year lease on 7,243 square feet.
Read MoreLondon-based Achilles Therapeutics picks Philadelphia for its first U.S. location

The company, which is developing cancer therapies by using DNA sequencing from individual patients, signed a three-year lease on 7,243 square feet.
Read MoreNew owners of part of the Hahnemann complex hope to tap in to surging demand for research and development laboratories.
Read More